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ABSTRACT
Introduction: Advancements in chemotherapy
treatment have improved the clinical
management of metastatic colon cancer
(mCC) patients. An increasing number of
elderly mCC patients receive various
combinations of regimens in second-line
chemotherapy/biologics treatment (Tx2) after
first-line treatment (Tx1) to prolong survival
and/or palliate symptoms, but these regimens
have higher costs. This analysis investigated the
survival benefit and incremental cost associated
with Tx2 among elderly mCC patients.
Methods: Elderly (aged C66 years) SEER-
Medicare patients diagnosed with mCC in
2003–2007 were identified and followed until
death or the end of 2009. Cox regression and
partitioned least squares regression were utilized
to obtain the survival benefit and incremental
cost associated with Tx2 within a 5-year study
period. A time-varying model was used to
reduce bias due to sequential ordering of Tx1
and Tx2. The regressions controlled for patient
demographic characteristics, clinical variables,
and a proxy for poor performance.
Bootstrapping was used to generate 95%
confidence intervals (CI).
Results: Of the 3,266 elderly mCC patients
who received Tx1, 2,744 (84%) died within the
observation period; 1,440 (44%) received Tx2.
The survival benefit associated with receipt of
Tx2 was 0.33 years (95% CI 0.19–0.43), and the
associated incremental cost was $40,888 (95%
CI 3,044–44,324). The incremental cost-
effectiveness ratio (ICER) for Tx2 was $123,903
per life year gained (95% CI 9,600–216,082).
Conclusion: The estimated survival benefit of
receiving second-line chemotherapy/biologics
was about 4 months, which is consistent with
evidence from clinical trials. This improved
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survival was associated with an ICER that
exceeds the traditional threshold.
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INTRODUCTION
Chemotherapy drugs and biologics developed
over the past decade have advanced the
management of first-line treatment (Tx1) and
second-line treatment (Tx2) for metastatic
colon cancer (mCC) patients. New treatments
come with improved survival and also with
significant increases in the cost of care for mCC
patients. The various combinations of regimens
utilized in Tx1 and Tx2 in real-world practice
impose challenges in understanding the
incremental survival benefit as well as the
associated cost with respect to the receipt of
Tx2. A comprehensive examination of Tx2 as
compared to Tx1 alone provides valuable
information that can help clinicians and mCC
patients make treatment decisions with respect
to the benefits and costs of multiple lines of
chemotherapy drugs and biologics. A detailed
analysis of the incremental cost of Tx2 among
elderly mCC patients can assist potential
stakeholders to better understand the cost
implications of improving the delivery of
high-quality cancer care.
The National Comprehensive Cancer
Network colon cancer guideline recommends a
list of chemotherapy drugs [i.e., 5-fluorouracil
(5-FU) and leucovorin (LV), irinotecan (IRI)
and oxaliplatin (OX)] and biologics
[i.e., bevacizumab (BEV), cetuximab, and
panitumumab] for mCC patients. IRI and OX
(IROX) can also be administered together with/
without 5-FU/LV to mCC patients [1]. These
primary treatments help to palliate symptoms
and prolong survival. The recommended
management strategies are based on evidence
from randomized clinical trials (RCTs) [2–11].
However, real-world benefit of Tx2 among
elderly mCC patients who have multiple
comorbidities may differ from those enrolled in
RCTs. Furthermore, a large portion of elderly
mCC patients who receive Tx1 may not receive
Tx2 or subsequent treatment line (TxS) due to
multiple comorbid conditions, tumor responses,
and severe side effects [12, 13]. Retrospective
cohort studies are useful to assess the
effectiveness of Tx2 as compared to Tx1
for mCC, which provides complementary
information to those obtained from RCTs to
improve clinical practices to ‘real world’ patients,
especially populations not studied in RCTs.
Given the rising cost of oncology care, the
survival benefit and incremental cost associated
with Tx2 for elderly mCC patients are
particularly relevant to payers, such as
Medicare. Moreover, the real-world survival
benefit of Tx2, overall cost and cost-
effectiveness of Tx2 can also help clinicians to
communicate with patients more efficiently




The surveillance epidemiology and end results
(SEER)-Medicare data were used to identify
elderly Medicare beneficiaries with mCC
diagnoses. The SEER-Medicare data are the
result of the linkage between SEER cancer
registry data and Medicare claims data. The
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SEER program was conducted by the National
Cancer Institute to provide demographic and
clinical information for all incident cancer cases
in 17 geographic regions in the USA. Medicare,
administered by the Centers for Medicare and
Medicaid Services, is the primary healthcare
provider for the elderly (aged C65 years) in the
USA, which collects information about covered
healthcare services from time of enrollment
until death.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors. The
approved Institutional Review Board protocol
number is HP-00049426.
Inclusion and Exclusion Criteria
The study population consisted of SEER-
Medicare enrollees (aged C66 years at the
time of diagnosis) diagnosed with mCC
between 2003 and 2007. Tumor location was
identified using the site recode variable in
SEER-Medicare, ranging from 15 to 23
(15 = cecum, 16 = appendix, 17 = ascending
colon, 18 = hepatic flexure, 19 = transverse
colon, 20 = splenic flexure, 21 = descending
colon, 22 = sigmoid colon, 23 = large
intestine). All patients needed to have
Medicare Parts A and B for a full year prior to
cancer diagnoses for accurate ascertainment of
baseline comorbidities; therefore, patients
enrolled in a managed care plan within 1 year
prior to cancer diagnosis were excluded. Those
who were diagnosed post-mortem were also
excluded. The remaining patients were followed
up through death or the end of 2009. Patients
were censored from the study upon loss of
complete Medicare coverage or enrollment in a
managed care plan.
Identification of Treatment Lines
and Associated Costs
The algorithm used for identifying treatment
lines was developed by Bikov et al. [14], which is
a claim-based algorithm used to identify initial
and subsequent treatment lines. This study
adopted the Medicare system perspective in
the cost analysis and included direct medical
costs reimbursed under Medicare Parts A and B,
i.e., drug costs, hospitalization costs and
physician fees.
Patient-Level Factors Included
in the Survival and Cost Analyses
Patient-level clinical variables included poorly
graded tumor, surgery of primary site, and
surgery of liver metastases. Indicators were
created for poorly graded tumor and surgery of
primary site, respectively. A categorical variable
was created for surgery of liver metastases: (1)
none; (2) surgery to other sites; and (3) ablation
of liver metastases with/out surgery to other
sites. Charlson comorbidity index (CCI) was
measured using claims within 1 year prior to
cancer diagnosis [15, 16]. A proxy for poor
performance status was created to detect any
hospital bed use, oxygen use, walking aid use
or wheel chair use within 3 months prior to
cancer diagnosis [17]. Patient demographic
information such as age, gender, marital status,
urban living status, and race/ethnicity were also
included in regression analyses. Age was defined
as a categorical variable (each 10-year increment
in age at the time of diagnosis). Race/ethnicity
was categorized into Non-Hispanic White,
African American, Hispanic White, and Asian.
Contextual variables, i.e., indicators for year of
diagnosis (2003–2007) and the SEER registry
sites were also included in the analyses.
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Statistical Methods
Patient-level factors were examined by the
number of chemotherapy/biologics treatment
lines: no treatment (Tx); Tx1 only; or Tx2, which
included those who received two or more lines.
The column distributions of each patient-level
factor for the Tx1 only group and the Tx2 group
were compared with the no Tx group. In this
unadjusted analysis, p values were generated to
measure the statistical differences between the
corresponding column percentages, where the
no Tx group was the reference group.
Because there is a sequential ordering from
Tx1 to Tx2, on average patients who received
Tx2 lived longer than those who received Tx1
only. A time-varying Cox regression framework
was used to examine the incremental survival
benefit associated with Tx2 to address this
‘‘immortal time bias’’ [18]. The time-varying
modeling approach assigned a patient in the
‘control’ group during the time period of Tx1
and switched her/him to the ‘experiment’
group at the time of initiation of Tx2. As
compared with the static modeling approach,
where patients were categorized into two groups
according to their final treatment status
(received Tx1 only versus Tx2), the time-
varying modeling approach took the dynamic
process of patients’ change of treatment status
into consideration, which reduced the bias of
the survival benefit associated with Tx2. We
conducted both static and time-varying
modeling approaches and compared the
survival benefits associated with Tx2 using the
Cox regression framework.
Individual mCC patients had different
probabilities of receiving treatment(s) according
to a specific set of patient-level clinical and
demographic variables. The inverse probability
weighting (IPW) method was used to control for
the self-selection issue into treatment(s).
Multivariate sequential logistic regressions were
utilized to estimate individual patients’
probabilities of receiving Tx1, Tx2 and TxS,
respectively. Two more variables were added in
this step: (1) state buy-in status, which is
indicative of low socioeconomic status; and (2)
household median income, which measures the
income level of the neighborhood defined by the
zip code of the patient’s residence. We used this
variable as an additional proxy for patients’
socioeconomic status, as has been done in prior
studies [19]. The combination of the time-
varying Cox regression framework and IPW
method offered a flexible framework, where
individual patients’ IPW weights were updated
depending on their treatment status, e.g.,
switching from Tx1 to Tx2.
Patients were also subject to censoring over
time. Each month, a certain percentage of
identified mCC patients were censored either
due to end of study or switching to a health
maintenance organization plan. The Lin’s
regression method was proposed to reduce the
bias due to patients’ missing information of
their future cost accumulation elsewhere [20].
This method inflates the costs of those patients
who are still alive and uncensored
proportionally to the percentage of patients
who are censored during each month. The
monthly incremental cost associated with Tx2
was obtained by a multivariate regression,
which measures the difference in costs of
patients who were actively in Tx2 with those
who were actively in Tx1. The overall
incremental cost of Tx2 over the 5-year period
was the sum of all 60 monthly costs that could
be attributed to Tx2 versus Tx1 [21]. An elderly
mCC patient would be in the ‘control’ group
(Tx1 group) and switched to the comparison
group (i.e., Tx2 group) later on according to the
treatment status in a particular month.
Therefore, the cost analysis of Tx2 is also time
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varying in essence. The incremental cost-
effectiveness ratio (ICER) was created by the
ratio of overall incremental cost and survival
benefits associated with Tx2.
The static modeling of the incremental cost
associated with Tx2 was obtained by comparing
the Tx2 group with the Tx1 only group
according to their final treatment status.
Similar multivariate regressions were
conducted as in the time-varying approach;
however, the control group and comparison
group remained unchanged over time. The
corresponding ICER of the static modeling was
also generated. Both time-varying and static
modeling approaches used bootstrapping
method to generate the 95% confidence
intervals (CI) for the ICERs [22]. We assumed
that there is a positive rate of time preference
that patients would like to postpone cost in the
future, thus separate analyses were conducted
to discount the cost at 3 and 5% annually to
year 2010 dollars [23]. The statistical
significance level was set a priori at a = 0.05.
RESULTS
As shown in Fig. 1, out of the 7,950 elderly mCC
patients in the dataset, only 3,266 (41%)
received any treatment, and 44% of Tx1 users
(1,440 out of 3,266) received Tx2. Receipt of Tx2
was associated with a lower 1-year mortality rate
(13%) compared with those who did not receive
chemotherapy treatment (88%) or received Tx1
only (53%). The median time from diagnosis
(Dx) to Tx1 and Tx2 was approximately
2 months and 12 months, respectively.
Table 1 shows the distribution of number of
treatment lines by patient-level factors. In the
unadjusted analysis, all clinical variables had an
impact on the receipt of treatment: (1) higher
CCI was associated with lower utilization rate of
any treatment(s); (2) poorly graded tumor was
associated with higher likelihood of receiving
any chemotherapy treatment; (3) indicator for
surgery of primary site increased the likelihood
of receiving Tx1 and Tx2; and (4) patients who
had ablation of liver metastasis or surgeries to
other sites were associated with higher
likelihood of receiving Tx1 and Tx2. Elderly
mCC patients with the indicator of proxy for
poor performance status had less chance of
receiving chemotherapy treatment. Being older
at the time of diagnosis was associated with
lower likelihood of receiving Tx1, Tx2 and TxS.
Being married was associated with higher
percentages of patients receiving further
treatment. Non-Hispanic White race was
associated with higher utilization rate of
Fig. 1 A diagram of elderly mCC patients switching to Tx1 and Tx2. Dx diagnosis, IPW inverse probability weighting,
mCC metastatic colon cancer, Tx1 ﬁrst-line treatment, Tx2 second-line treatment
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Table 1 Distribution of number of treatment lines by patient-level factors
Total (N 5 7,950) No Tx Tx1 only Tx2
(N 5 4,684) (N 5 1,826) (N 5 1,440)
N Col % N Col % p* N Col % p
CCI
CCI = 0 2,667 57 1,160 64 \0.0001 975 68 0.014
CCI = 1 1,023 22 424 23 312 22
CCI = 2 530 11 150 8 97 7
CCI = C3 464 10 92 5 56 4
Poorly graded tumor
Yes 1,105 24 542 30 \0.0001 395 27 0.033
No 3,579 76 1,284 70 1,045 73
Surgery of primary site
Yes 2,293 49 1,295 71 \0.0001 1,139 79 \0.0001
No 2,391 51 531 29 301 21
Surgery of liver metastases
Ablation of liver metastasis 319 7 257 14 \0.0001 211 15 0.515
Surgery to other site(s) 173 4 98 5 64 4
None 4,192 90 1,471 81 1,165 81
Proxy for poor performance status
Yes 601 13 104 6 \0.0001 44 3 \0.0001
No 4,083 87 1,722 94 1,396 97
Age at time of Dx
66–74 1,100 23 809 44 \0.0001 797 55 \0.0001
75–84 2,057 44 841 46 592 41
C85 1,599 33 176 10 51 4
Female
Yes 2,671 57 952 53 \0.0001 708 49 0.004
No 2,013 43 874 47 732 51
Married
Yes 1,739 37 992 54 \0.0001 905 63 \0.0001
No 2,945 63 834 46 535 37
Urban living area
Yes 4,197 90 1,620 89 0.068 1,309 91 0.021
No 487 10 206 11 131 9
Race/ethnicity
Non-Hispanic White 3,665 78 1,470 81 0.003 1,191 83 \0.0001
African American 592 13 184 10 122 8
Hispanic 218 5 94 5 62 4
Asian 209 4 78 4 65 5
CCI Charlson comorbidity index, CoI column, Dx diagnosis, Tx treatment, Tx1 ﬁrst-line treatment, Tx2 second-line treatment
* p measures the statistical signiﬁcance of the difference between column percentages of no Tx group and another group (i.e., Tx1 only and
Tx2 and above)
 p measures the statistical signiﬁcance of the difference between column percentages of Tx1 only and Tx2
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chemotherapy treatment as compared to
African American race.
Figure 2a shows the 5-year survival curves of
elderly mCC patients by number of treatment
lines. The standard multivariate Cox regression
framework categorized patients into groups
according to the number of treatment lines
received. The survival benefit associated with
Tx2 as compared to Tx1 was measured by the
difference between the areas under the curves of
Tx1 and Tx2 (Table 2). The mean survival
difference between the Tx2 and Tx1 groups
was 0.76 years (95% CI 0.62–0.89).
Figure 2b shows the 5-year survival curves
calculated from the time-varying IPW Cox
regression framework. The survival benefit
associated with Tx2 was measured by calculating
the difference between the survival probabilities
of patients who were actively receiving Tx1 and
those who were actively receiving Tx2. The mean
survival benefit obtained from time-varying
modeling was 0.33 years (95% CI 0.19–0.43)
(Table 2). Compared with the survival benefit
from the static modeling approach, the survival
benefit was much smaller in the time-varying
model that accounted for the time when patients
switched from Tx1 to Tx2.
Table 2 reports the incremental cost
associated with Tx2 using the static and the
time-varying partitioned IPW cost regression
frameworks, respectively. In contrast to the
static modeling where patients were grouped
according to classifying event (i.e., receipt of
Tx2), the time-varying modeling calculated the
difference in monthly costs between mCC
patients who were actively receiving Tx2 and
those who were actively receiving Tx1,
adjusting for all patient, provider, and hospital
level characteristics. The incremental cost
associated with Tx2 was $82,615 (95% CI
76,883–131,366) in the static modeling and
$40,888 (95% CI 3,044–44,324) in the time-
varying modeling. The reduction in the
incremental cost associated with Tx2 reflected
the reduction in the bias introduced by
categorizing elderly mCC patients into the Tx2
group while they were in Tx1.
The ICER of Tx2 was $109,870 per life year
gained (95% CI 82,513–131,366) in the static
modeling and $123,903 per life year gained
(95% CI 9,600–216,082) in the time-varying
modeling. In contrast to a moderate increase in
the ICER from the static modeling to time-
varying modeling, there was a substantial
increase in the 95% CIs. The increased
Fig. 2 Cox regression results survival analysis: a stratiﬁed
analysis; b time-varying analysis. The black and red lines
represent the survival probabilities over time for patients
who received Tx1 only and Tx2 as the last treatment line,
respectively. Tx1 ﬁrst-line treatment, Tx2 second-line
treatment
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variability of the ICER is largely due to
individual mCC patients’ prognoses and the
resulting change of treatment status.
Figure 3 shows the impact of timing of
initiation of Tx2 and duration of Tx2 on the
predicted overall incremental cost associated
with Tx2. Patients were categorized into three
groups according to their timing of initiation of
Tx2: early initiation group (B18 months since
diagnosis), intermediate initiation group
(19–36 months), and late initiation group
([36 months). In general, earlier initiation was
associated with lower incremental cost for Tx2
among patients who had the same duration of
Tx2. The longer the time period that a patient
stayed in Tx2, the higher the cost associated
with Tx2.
DISCUSSION
Our study examined the overall cost-
effectiveness of second-line chemotherapy
among real-world elderly mCC patients. Given
the enriched and complex chemotherapy
treatment options available to mCC patients,
it would have been difficult to recruit and
randomize a large number of patients into
different treatment strategies using a clinical
trial approach. Our retrospective study adopted
the IPW method and time-varying Cox
regression framework to reduce bias due to
patients’ selection into treatment. Combined
with the time-varying cost analysis, our paper
provides an ICER for Tx2 among elderly mCC
patients, which can facilitate the planning and
management of chemotherapy and biologics
treatments.
A review study summarized the evidence of
survival benefit of different regimens in Tx2
from RCTs [24]. A number of conclusions were
made regarding the best treatment options after
various initial treatments: Tx2 with active
regents was superior to best supportive care;
following 5-FU failure, IROX was superior to IRI;
Table 2 Partitioned IPW: survival/cost analysis of Tx2 treatment (discounting to year 2010 dollars)
r5 0% r5 3% r5 5%
Estimate 95% CIs Estimate 95% CIs Estimate 95% CIs
Stratiﬁed analysis
Incremental cost ($) 82,615 (76,883–88,827) 91,437 (85,108–98,245) 97,780 (91,025–104,962)
Incremental
survival (years)
0.76 (0.62–0.89) 0.76 (0.62–0.89) 0.76 (0.62–0.89)
ICER 109,870 (82,513–131,366) 121,614 (102,548–145,457) 130,053 (109,695–155,534)
Time-varying analysis
Incremental cost ($) 40,888 (3,044–44,324) 44,881 (3,205–48,643) 47,734 (3,370–51,721)
Incremental
survival (years)
0.33 (0.19–0.43) 0.33 (0.19–0.43) 0.33 (0.19–0.43)
ICER 123,903 (9,600–216,082) 136,003 (10,948–237,271) 144,648 (11,692–252,476)
r (0, 3, 5%) represents patients’ willingness to postpone costs in the future
CI conﬁdence interval, ICER incremental cost-effectiveness ratio, IPW inverse probability weighting
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following IRI, OX was in general the best choice,
and OX ? BEV seemed to be superior to OX
alone. Following OX, IRI was superior to other
options. Our study included various scenarios of
Tx1, Tx2, and TxS in clinical practice, which
provides complementary information for the
treatment effect of Tx2 among elderly mCC
patients. We also concluded that the later the
initiation of Tx2, the steeper the slope of cost
trajectory associated with Tx2. Future research
should compare the survival/cost differences
between Tx1 and Tx2 across treatment
regimens. However, this would require a larger
number of mCC patients in each treatment
scenario to have reliable estimates of the cost-
effectiveness of various combinations of
chemotherapy and biologics.
Our cohort consisted of elderly mCC patients
with diagnoses between 2003 and 2007. Their
chemotherapy treatments were followed up until
2009. Our analysis is limited by the fact that
newer biologics that were introduced into the
treatment for mCC were not included. Newer
biologics that were developed after 2009 and
utilized in Tx2 might improve the survival
benefit associated with Tx2 among elderly mCC
patients. Depending on the costs associated with
these newer regimens in Tx2, the corresponding
ICER might be higher or lower than the
estimation from our analysis. In addition, our
analysis did not include Medicare prescription
drug benefit, due to the availability of the data.
The cost analysis used nominal dollars, which did
not use the Consumer Price Index to adjust for
inflation. We did not discount the survival. Also,
utilizing utility weights could also further affect
the ICER of Tx2. Moreover, we used a claim-based
algorithm to identity chemotherapy treatment
lines among Medicare beneficiaries. The survival
benefit, costs and cost-effectiveness of Tx2
may not be readily applied to non-elderly
populations. Further efforts are needed to
examine the cost-effectiveness of Tx2 among
younger populations.
Fig. 3 Individual elderly mCC patients’ cost by duration
of Tx2. The x-axis represents the duration of Tx2 and the
y-axis represents the incremental cost associated with Tx2.
Dx diagnosis, mCC metastatic colon cancer, Tx1 ﬁrst-line
treatment, Tx2 second-line treatment
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CONCLUSION
Less than half of elderly mCC patients initiated
chemotherapy/biologics treatment. Among
those treated, less than half received second-
line treatment. The estimated survival benefit of
receiving second-line chemotherapy/biologic
treatment is about 4 months, which is
consistent with evidence from clinical trials.
Time-varying modeling of the survival benefits
and associated costs substantially reduced the
bias that existed in the traditional stratified
analysis. This improved survival was associated
with an incremental cost-effectiveness ratio that
exceeds the traditional threshold.
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